172 results about "Guanosine" patented technology

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention discloses a symmetric nucleoside microneedle patch loaded with polymer vesicles as well as a preparation method and application of the symmetric nucleoside microneedle patch. The symmetric nucleoside microneedle patch loaded with the polymer vesicles comprises a guanosine-quadruplex hydrogel microneedle tip doped with drug-loading polymer vesicles, the raw material of the drug-loaded polymer vesicle comprises a polycaprolactone-polyglutamic acid copolymer; the guanosine-quadruplex hydrogel is prepared from the following raw materials: guanosine and KB (OH) 4. The microneedle patch is constructed on the basis of dynamic covalent bond and non-covalent interaction, has a sharp tip array capable of penetrating the epithelium and the lower layer of a mucous membrane, can efficiently deliver a drug to a canker lesion part by bypassing a mucous membrane barrier, can be controllably broken under a high ROS condition of an inflammation microenvironment, has the characteristics of high drug delivery efficiency and high accuracy, and can be used for preparing a medicine for treating the canker lesion part. The effect of effectively improving chemotherapy-induced oral ulceration can be achieved by reducing inflammatory response, relieving pain feeling and inhibiting pain sensitization.

The invention discloses a high-flame-retardant bio-based aerogel material and a preparation method thereof, and belongs to the technical field of flame-retardant bio-based aerogel. The high-flame-retardant bio-based aerogel material prepared by the preparation method disclosed by the invention is prepared from the following raw material components in parts by mass: 10 parts of a bio-based flame-retardant filler with a porous structure, 40 to 50 parts of a hydrophobic siloxane monomer, 12.4 to 12.6 parts of an ammonium phytate solution, 6.2 to 6.3 parts of guanosine, 31.1 to 31.4 parts of cellulose nanofibers and 0.01 to 0.02 part of benzaldehyde-polyethylene glycol-silane, the preparation method comprises the following steps: firstly, carrying out hydrolytic polycondensation on a bio-based flame-retardant filler with a porous structure and a hydrophobic siloxane monomer to form a siloxane polymer network with the bio-based flame-retardant filler as a branching center; then adding cellulose nanofibers, guanosine and an ammonium phytate solution, and performing freeze casting-freeze drying-heating post-treatment to obtain the composite material. Wherein the bio-based flame-retardant filler is obtained by compounding a porous cuttlefish ink carbon quantum dot composite material with phytic acid siloxane and trimethoxy (3-(4-nitrophenoxy) propyl) silane.

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and the deterioration in flavor due to the reduction in purine concentration is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 5-methylfurfural concentration is 10 ppb or more.

The present invention relates to certain compounds that function as inhibitors of enzymes which binds guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP) or 5' guanosine triphosphate (GTP) capped RNA, such as enzymes which comprise a RNA cap Guanine N-7 methyl transferase. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of viral infections, as well as other diseases or conditions in which activity of such enzymes is implicated. (Formula (I)

The invention discloses supramolecular hydrogel and microneedle patch for treating oral mucositis and a preparation method and application thereof, and belongs to the technical field of biological medicine, and the supramolecular hydrogel for treating oral mucositis comprises the following raw materials: guanosine, a potassium hydroxide solution containing metal ion soluble salt and phenylboronic acid lactone drugs. The raw material of the microneedle patch further comprises a water-soluble backing solution. The supramolecular hydrogel or microneedle patch for treating oral mucositis integrates antibacterial, anti-inflammatory, antioxidant and angiogenesis promoting functions, and has a remarkable effect of promoting healing of chemotherapeutic oral mucosal lesion.

According to the present invention, a method for producing a hot water extract of an aboveground portion of a plant of the genus aralia is characterized by comprising a step for adding sodium hydrogen carbonate.

2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 21) and its phosphoramidate prodrug (FMCAP, 31) have demonstrated potential anti-HBV activity against both adefovir- resistant as well as lamivudine-resistant double (rtL180M / rtM204V) mutant hepatitis B virus (HBV). In addition, in vitro, these molecules have reinstated a significant activity against lamivudine / entecavir triple mutants (L180M+S202G+M204V). This invention is directed to compounds, pharmaceuticals and methods of treating HBV infections, especially including infections caused by resistant and multiple resistant HBV. Pursuant to the present invention, a complete structure-activity relationship (SAR) of 2'-fluoro-6'-methylene-carbocyclic derived nucleos(t)ides has been evaluated and that analysis is presented herein. Pursuant to the present invention, the synthesis and antiviral evaluation of purine and pyrimidine-derived nucleosides have been reported against wild-type and various HBV mutants. Guanosine analog (FMCG, 25) demonstrated an EC50 value of 0.217μM and cytosine analog (FMCC, 41) expressed a potent EC50 value of 0.0025 μM compared to entecavir (EC50 = 0.0029) against wild-type HBV. Additionally, FMCC (41) maintains its antiviral potency against various HBV mutants. Furthermore, chiral pure FMCAP Sp (34) isomer demonstrated an EC50 value of 1.3 nM and was more potent against several HBV mutants than entecavir.

The invention relates to the technical field of dye separation, and discloses a loose nanofiltration membrane and a preparation method and application thereof, the loose nanofiltration membrane comprises a porous support membrane, and a polyesteramide separation layer formed on the porous support membrane through one-step interfacial polymerization of nucleoside monomers and multi-acyl chloride monomers. The nucleoside monomer is one or more than two of adenosine, guanosine and cytidine nucleoside. The nucleoside monomer with a long-chain structure, a branched-chain structure, a rigid twisted structure and a plurality of hydrophilic reaction sites is selected as an interfacial polymerization water-phase monomer, so that the loose nanofiltration membrane is endowed with excellent permeation and separation performance. The membrane has a high rejection rate on dye molecules such as Congo red and methyl blue, also has high water permeability and extremely high dye / inorganic salt separation selectivity, and shows good application potential in the aspects of dye production and purification and dye wastewater recovery.

This invention relates to a potassium ion-responsive hydrogel based on iminoboronic ester bonds, its preparation method, and its applications. The hydrogel is prepared using guanosine, 2-formylphenylboronic acid, and polyoxyethylenediamine. The diol of guanosine forms a borate ester bond with 2-formylphenylboronic acid, and the primary amine in the polyoxyethylenediamine forms an imino group with the aldehyde group of 2-formylphenylboronic acid. The bases of guanosine form a G-quadruplex under the influence of potassium ions. The hydrogel has a porous network structure. The preparation method is as follows: A mixed aqueous solution of guanosine, 2-formylphenylboronic acid, and polyoxyethylenediamine is heated to boiling to obtain a clear solution. After cooling, the solution is mixed with a potassium ion solution to prepare the potassium ion-responsive hydrogel based on iminoboronic ester bonds. Compared with the prior art, the hydrogel prepared by this invention exhibits both temperature and potassium ion responsive characteristics.

The present disclosure relates generally to (CRISPR) RNA (crRNA) for the precision silencing of transcripts. In some embodiments, the crRNA are enriched for guanosine (G) nucleotides at key spacer positions, which is useful in enhancing the silencing efficacy of otherwise inefficient crRNA, thereby expanding the targeting spectrum of Cas13 endonucleases, e.g., Cas13b and Cas13d. In other embodiments, the crRNA comprise a spacer sequence having at least one nucleotide mismatch relative to the target RNA sequence, wherein the target RNA sequence is a wild-type transcript and / or a variant transcript (e.g., a transcript comprising a single nucleotide variant (SNV)). The present disclosure also provides RNA editing systems comprising the crRNA described herein in complex a Cas13 effector protein and a target RNA sequence, methods for the selective targeting of transcripts encoding proteins that are difficult to target, or are not amenable to pharmacological targeting, e.g., oncogenic fusion transcripts or oncogenic transcripts comprising single nucleotide variant(s), and methods for the design and selection of potent crRNA.

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The invention relates to a novel modified trinucleotide capped derivative and mRNA introduced with the capped derivative, a methylene bridged heterocyclic compound and a derivative of aryl methyl are respectively introduced at the N7 position of 5 '-terminal guanosine base, and the efficiency is superior to that of a capped substance used in an existing mRNA vaccine; therefore, the present invention can be effectively used in the fields of development of mRNA vaccines and development of various mRNA-based therapeutic agents.

A method for increasing or improving nitric oxide signals or levels, the method comprising: administering a composition to a subject, the composition comprising: arginine or a pharmaceutically acceptable salt, ester, or derivative thereof; and tetrahydrocurcumin and / or β-aminoisobutyric acid or a pharmaceutically acceptable salt or ester thereof. The method and the composition can be used to increase, improve, or enhance nitric oxide signals or levels, inhibit nitric oxide decomposition, and increase or enhance nitrous acid and / or cyclic guanosine monophosphate levels, and can improve fatigue resistance or enhance muscle strength, maintain or improve cardiovascular health, maintain or improve vascular function and structure, inhibit or mitigate endothelial cell damage, or mitigate insufficient blood flow.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

This invention relates to the field of traditional Chinese medicine detection technology, specifically providing characteristic chromatograms of germinated rice or roasted germinated rice and their preparations, and their construction methods. Using octadecylsilane-bonded silica gel as the packing material, the mobile phase includes methanol and formic acid aqueous solution, gradient elution, and a specific elution program obtained through extensive experimental screening, yielding more than 13 common characteristic peaks. Effective separation of characteristic peaks including uridine, adenosine, guanosine, 5-hydroxymethylfurfural, 4-coumaric acid, and ferulic acid is achieved, with good peak shape, stable baseline, complete separation of the measured components, and short detection time. This provides a basis for the quality detection and control of germinated rice or roasted germinated rice and their preparations, fully reflecting the integrity and characteristics of germinated rice or roasted germinated rice and their preparations. The method is simple to operate and applicable to the quality control of different types of germinated rice or roasted germinated rice preparations.

An oligonucleotide molecule has 10 to 50 nucleotides that include at least one G-quartet forming motif having 10 to 20 nucleotide residues. At least 60% of the residues of the G-quartet forming motif are guanosine or deoxyguanosine residues. The oligonucleotide molecule inhibits tumor growth and / or viral or bacterial replication and / or exerts anti-inflammatory effects in mammalian cells.

The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.

The present application relates to the cosmetic technical field, specifically to a composition containing guanosine component and capable of promoting scalp epidermal cell regeneration and a preparation method, which comprises the following raw material components in percentage by weight: 0.5-20% of surfactant AES, 0.5-10% of biota extract, 0.5-12% of pueraria extract, 0.5-12% of ginger extract, 0.5-10% of ginsenoside extract, 0.5-10% of hydrolyzed corn starch, 0.2-2% of tetraphosphoric acid di-guanosine (GP4G), 1-10% of base liquid, 1-5% of humectant, 0.1-2% of thickening agent, 0.01-1.0% of preservative, and the rest is deionized water. The formula has no irritation, is mild, can significantly increase hair growth and hair volume, increase hair follicle hair retention, inhibit hair loss, promote the re-development of hair follicles, has very significant dandruff and itching relieving functions, and has a simple operation process, and is suitable for industrial manufacturing.

This invention relates to the fields of environmental chemistry and biological sample analysis, specifically to an analytical method for detecting oxidative stress biomarkers in urine. Based on liquid chromatography-tandem mass spectrometry (LC-MS / MS), this invention provides an analytical method for the simultaneous detection of dityrosine, 8-hydroxyguanosine, 8-hydroxydeoxyguanosine, and 4-hydroxynonenal mercaptouric acid in human urine. This method achieves effective purification of urine samples through specific pretreatment, reducing matrix effects, and, combined with specific LC parameters, enables the simultaneous detection of four oxidative stress biomarkers. This method exhibits good selectivity, high sensitivity, and fast detection speed, solving the current problem of the inability to simultaneously determine polar and nonpolar components. It includes a more comprehensive and rational list of oxidative stress biomarkers, better reflecting the body's oxidative stress damage.

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof, and pharmaceutical preparations or dosage forms containing them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases, in which increased sGC stimulation, or increased concentrations of nitric oxide (NO) or cyclic guanosine 3',5'-monophosphate (cGMP), or both, or upregulation of the NO-sGC-cGMP pathway is desired. Compounds useful in the methods of the present invention are of Formula I or pharmaceutically acceptable salts thereof:

The invention provides lactobacillus reuteri and an application thereof. The lactobacillus reuteri provided by the invention has a preservation number of CGMCC (China General Microbiological Culture Collection Center) NO. 32834 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The lactobacillus reuteri provided by the invention can inhibit the activity of xanthine oxidase, promote the degradation of creatinine and guanosine, remarkably reduce the content of blood uric acid, reduce the content of creatinine and urea nitrogen, slow down tissue damage caused by hyperuricemia, improve the health level of damaged tissues caused by hyperuricemia, and improve the quality of the tissue damaged by hyperuricemia. Meanwhile, the probiotics have multiple beneficial effects in the aspects of eliminating inflammation, enhancing the immune function and the like, and the problem that existing uric acid reducing probiotics are insufficient in effectiveness is solved. The application can be used for developing microecological preparations, functional foods or nutritional supplements which are mainly used for reducing uric acid and have multiple effects (one bacterium has multiple purposes), and has a good industrialization prospect.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The invention relates to the technical field of biological medicine, in particular to guanosine oxidation piRNA-014733, antisense nucleotide and application of the guanosine oxidation piRNA-014733 and the antisense nucleotide. The guanosine oxidation piRNA is named as o8G piRNA-014733, the guanosine oxidation piRNA is related to the regulation and control of myocardial ischemia reperfusion injury and myocardial cell ferroptosis, and the nucleotide sequence of the o8G piRNA-014733 gene is shown as SEQ ID NO. 1. The antisense nucleotide sequence of the o8G piRNA-014733 is as shown in SEQ ID NO. 2, and the antisense nucleotide sequence is as shown in SEQ ID NO. The expression of the o8G piRNA-014733 provided by the invention in heart tissues suffering from ischemia reperfusion injury and myocardial cells suffering from ferroptosis is remarkably up-regulated, and the o8G piRNA-014733 antisense nucleotide provided by the invention can be used for down-regulating the expression level of the o8G piRNA-014733 and inhibiting the ferroptosis of the myocardial cells.

Provided herein are methods and compositions for the synthesis of 5 '-capped RNA wherein the starting capped oligonucleotide primer has the general form m7Gppp [N2' Ome] n [N] m wherein m7G is an N7-methylated guanosine or any guanosine analog, N is any natural, modified or non-natural nucleoside, "n" may be any integer from 0 to 4 and "m" may be an integer from 1 to 9.

The present disclosure generally relates to the use of linear nucleic acid primers for the amplification of a target nucleic acid sequence, for example, in a cell-free environment. In some embodiments, compositions of the linear nucleic acid primers are provided. For example, in some embodiments, the linear nucleic acid primers comprise a guanosine or a cytidine at 3′ terminal end. In some embodiments, the linear nucleic acid primers have been optimized to prevent primer-homodimer and / or hairpin formation and to exclude cumbersome codon sequences. In some embodiments, methods are provided for the amplification of a DNA template fragment using the linear nucleic acid primers. Thus, in some cases, the use of the nucleic acid primers, as described herein, may allow for the reduction in amplification of non-specific hybridization events while allowing for the amplification of the target nucleic acid sequence.

The invention relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology. Cyclic guanylate is small in molecular weight and poor in immunogenicity. When a corresponding antibody is prepared, a proper isomer and a derivative site need to be selected firstly, and a derivative hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic guanylic acid hapten, a cyclic guanylic acid complete antigen, preparation of an anti-cyclic guanylic acid antibody, a method for measuring the concentration of cyclic guanylic acid, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic guanylate derivative. The cyclic guanylate derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof, and pharmaceutical formulations containing them, and their uses, alone or in combination with one or more additional agents, for treating various diseases in which an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic guanosine monophosphate (cGMP), or both, or upregulation of the NO pathway, is desired. In some embodiments, the compound is of Formula I or a pharmaceutically acceptable salt thereof. (I) TIFF2025536343000075.tif3865